However, there has been no study to date investigating longer acting GLP-1 RA in individuals without overweight or obesity [49]
In Phase 2 trial imaging, fat mass fell substantially more than lean mass, so most of the weight lost was fat the muscle loss is real but is a minority of total loss and is in the same range as semaglutide and tirzepatide

The following table describes GLP-1 receptor agonists, their dosing frequency and key pharmacokinetic parameters: Cautions and Contraindications Adverse Effects Acute pancreatitis (rare) Injection site reactions Gastrointestinal disturbances (nausea, vomiting, diarrhoea dehydration and possible renal impairment) Increase in pancreatic enzymes: lipase and amylase (dulaglutide, tirzepatide and semaglutide) Cholecystitis and cholelithiasis Delayed gastric emptying (semaglutide, exenatide, dulaglutide, tirzepatide (diminishes over time)) Increased heart rate Diabetic retinopathy complications (semaglutide, particularly in insulin-treated patients with known diabetic retinopathy) Interactions GLP-1 receptor agonists do not interact via cytochrome P450 , but delayed gastric emptying may alter drug absorption

GHK-Cu might be more effective in someone with: Oxidative stress gene variants Poor copper transport capacity Collagen breakdown pathways In my next edition, Ill share how genomics, epigenetics, microbiome, metabolomics, and other advanced testing can guide smarter peptide use
T.KleinW
Comparison of the decrease in glycated hemoglobin levels of diabetic patients caused by a 40-week treatment with tirzepatide (5, 10 or 15 mg/wk) or semaglutide (1 mg/wk)